Corbus Doses First Patient in Registrational TEMPO-1 Trial for CRB-701
CRBP is trading near its 52-week low of $6.325 (12% above the low).
Summary
Corbus has dosed the first patient in its TEMPO-1 registrational study of CRB-701 in second-line oropharyngeal cancer. This follows FDA clearance in July and marks the official start of the pivotal trial. The study will enroll 250 patients and compare CRB-701 against investigator's choice of capecitabine, cetuximab, or docetaxel, with ORR as the primary endpoint for potential accelerated approval. Prior Phase 1/2 data showed a 42.9% confirmed ORR at the 3.6 mg/kg dose, supporting the registrational design. The company is also advancing CRB-913 in obesity, with positive Phase 1b data reported earlier this month.
At the time of this announcement, CRBP was trading at $7.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $6.33 to $20.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.